Understanding multi-stakeholder needs, preferences and expectations to define effective practices and processes of patient engagement in medicine development: A mixed-methods study

Stuart D Faulkner, Suzanne Sayuri II, Chi Pakarinen, Fabian Somers, Maria Jose Vicente Edo, Lucia Prieto Remon, Ana Diaz Ponce, Dianne Gove, Elisa Ferrer, Begonya Nafria, Neil Bertelsen, Mathieu Boudes, Nicholas Brooke, Alexandra Moutet, Nick Fahy

Abstract

Background: The holistic evolution of patient engagement in medicines development requires a more detailed understanding of the needs of all involved stakeholders, and one that better accounts for the specific needs of some potentially vulnerable patient populations and key stages in medicines development.

Objective: The purpose of this convergent mixed-methods study was to better understand the needs of different stakeholders concerning patient engagement at three key stages in medicines development: research priority setting, clinical trial design and early dialogues with Health Technology Assessment bodies and regulators.

Design: This study brought together findings from three sources: i) an online questionnaire, ii) face-to-face consultations with two potentially vulnerable patient populations, a workshop with Health Technology Assessment bodies, and iii) three-step modified Delphi methodology.

Results: Overall stakeholders still need additional varied support mechanisms to undertake, sustain or measure value of patient engagement. Health Technology Assessment bodies need better rationale for patient engagement in early dialogue and tools to support its implementation. Improved awareness and understanding of the need and value that involving patients, who are often considered as potentially vulnerable, can bring is needed, as is better accommodation of their specific needs. Similarly, weighted Delphi categories were as follows: aims and objectives, sustainability. Several additional themes were common across the three key stages in medicines development.

Conclusion: This broad-reaching study provides the blocks needed to build a framework for patient engagement in medicines development.
1 | INTRODUCTION

There is increasing consensus among stakeholders that patient engagement (PE) in medicines development is critical to fostering patient access to better designed innovative therapeutic solutions and delivering more effective health outcomes for patients. Key involved stakeholders include the patient community (patients, patient advocates and patient organizations), the pharmaceutical industry, regulators, health technology assessment (HTA) bodies, payers, health-care professionals (HCP), academia and to a certain extent policymakers and research funders. Although there are different perspectives on what PE means, here we define PE as ‘the effective and active collaboration of patients, patient advocates, patient representatives and/or carers in the processes and decisions within the medicines lifecycle, along with all other relevant stakeholders when appropriate’. While there are many initiatives to involve patients across that continuum, inconsistency and fragmentation remain the norm. This is especially so for the meaningful engagement of potentially vulnerable patient populations who often have additional or specific needs (such as people with dementia and young people). Patient engagement also needs to be understood better at key upstream stages of medicines development that are comparatively poorly serviced by current efforts such as research priority setting, clinical trial design and early dialogues with health technology assessment (HTA) bodies and regulators. Achieving systematic and meaningful PE are challenging and must meet the requirements and preferences of effective PE from all involved stakeholders, ii) potentially vulnerable patient populations, and a separate workshop with HTA bodies and regulators (and in some contexts with payers) regarding development plans for a medicinal product and to ensure they meet the requirements and iv) potentially vulnerable patients, in the context of this project, include (but are not limited to) people with dementia and their carers, and young people.

2 | DESIGN AND METHODS

This work was conducted within the context of the PARADIGM project, funded by the Innovative Medicines Initiative (IMI), that developed ways to ensure that patients are always meaningfully involved in the development of medicines. This study took a convergent mixed-methods approach combining quantitative methods and a qualitative approach, using consultations set within the framework of patient and public involvement (PPI). The learning and key emerging themes from each stage were incorporated into each following stage. This brought together three components: i) an online questionnaire to capture overall identification of needs, expectations and preferences of effective PE from all involved stakeholders, ii) separate face-to-face consultations with two specific groups of potentially vulnerable patient populations, and a separate workshop with representatives from HTA bodies – to gather greater insight on the needs and preferences of these groups beyond the results of a survey, and (iii) modified Delphi exercise to identify and prioritize the minimum agreed criteria for effective and meaningful PE at the three key stages of medicines development (Figure 1).

PARADIGM consortium partners AE and FSJD sourced patients involved in the two consultations from pre-existing working groups within each respective umbrella organization. Each was led by their own staff and followed its own standard institutional processes for organizing PPI activities. Delphi panel experts were identified from the PARADIGM consortium networks, and standard institutional processes were followed for undertaking the Delphi exercise.

The separate workshop with HTA bodies was overseen by the HTA international (HTAi) Patient & Citizen Involvement Group (PCIG) Steering Committee. For the network of HTA agencies and the European Network for HTA (EUnetHTA) Early Dialogues Working Party (EDWP), the French HTA agency, Haute Autorité de Santé (HAS), as the co-lead of this group, sought approval from the
HAS board for involvement in this project (see Bertelsen N, et al 2020, manuscript under submission to Health Expectations).

2.1 | Stage 1: Survey

This survey aimed to identify current needs and expectations for PE across medicines development. The survey was constructed in two phases. Firstly, issues identified from existing literature on PE in medicines development were prioritized during a face-to-face workshop involving a multi-stakeholder working group. This informed the structure of a survey which was piloted over two weeks using respondents from each respective stakeholder group.

The final survey was made up of 15 general questions that all stakeholder groups completed. Within this general section, two questions were constructed in matrices allowing more than one choice per row, six questions were structured as visual analogue scales (assigning 0-100 points based on respondents’ impressions on PE) and four questions were multiple-choice, allowing for more than one option to be chosen. Stakeholder groups: the patient community, industry, regulators, policymakers, HTA bodies and payers, research funders and HCPs (clinical academics) also had additional separate sections comprising matrices and multiple-choice questions. Within the survey, we initially sought to gain a broad benchmark of PE across the medicines lifecycle, including dialogues with regulators and HTA bodies that involve the licensing of medicines, HTA assessment, and pricing and reimbursement. Hereafter, the workshop with HTA bodies and Delphi panels only explored the definition of early dialogues with regulators and HTA.

The survey was administered in English in an online tool, Survey Gizmo, over a four-week period in 2018. A snowball technique was utilized to cascade the survey within consortium members’ internal and external networks to reach an estimated sample population of 10,000 (with 95% CI), with a minimum calculated sample size needed of 370.

All key stakeholders in medicines development were targeted: regulators, HTA bodies, industry (pharmaceutical, biotechnology and medical technology companies) health-care professionals (clinical academics), patients and patient representatives (from disease-specific or agnostic organizations, and non-affiliated individual patients), policymakers, research funders and research and academia (research institutes and universities).

Completed survey responses were converted and analysed using a statistical software package (IBM SPSS Statistics, Version 25.0, Amrock, NY: IBM Corp.) and Microsoft Excel (Version 16.20). Findings are described as total responses or percentage of respondents to a given question or theme.

2.2 | Stage 2: Face-to-face consultations and workshops

The specific needs, expectations and preferences of young people, and people with dementia and their carers were explored through separate face-to-face consultations, involving respective experienced staff, in order to better understand the specific PE needs of these groups of patients.

In the case of people with dementia, members of Alzheimer Europe’s (AE) European Working Group of People with Dementia (EWGPWD) and their carers participated in a one-day consultation...
## TABLE 1  Overall representativeness of the three stage, three panel Delphi experts

| Delphi panel                  | Round 1                      | Round 2                      | Round 3                      | Profiles of Stakeholders in Face-to-Face meetings |
|-------------------------------|------------------------------|------------------------------|------------------------------|---------------------------------------------------|
| Setting Research Priorities   | Women: 13 (65%) Men: 7 (35%) | Women: 11 (68.7%) Men: 5 (31.2%) | Women: 6 (60%) Men: 4 (40%) | Patients/Patient advocates/Pharmaceutical industry professional, HCP, Research and Academia, Regulator, Research Funder, Professional, Other |
|                              | <25:1:5% 35-44:4% 45-54:10% 55-64:4% >65:1(1%) | <25:1 (6.25%) 35-44:2 (12.5%) 45-54:9 (56.2%) 55-64:3 (18.7%) >65:1 (6.2%) | <25:1 (10%) 35-44:2 (60%) 55-64:1 (10%) |                                                    |
| Clinical Trial Design         | Women: 22 (75.8%) Men: 7 (24.1%) | Women: 20 (76.9%) Men: 6 (23.07%) | Women: 14 (77.7%) Men: 4 (22.2%) | Patients/Patient advocates/Pharmaceutical industry professional, HCP, Research and Academia, HTA body, Research Funder, Other |
|                              | <25:1:1.3% 25-34:2 (6.8%) 35-44:5 (17.2%) 45-54:18 (62.1%) 55-64:2 (6.8%) >65:1 (3.4%) | <25:1:3 (3.8%) 25-34:2 (7.6%) 35-44:5 (19.2%) 45-54:17 (65.3%) 55-64:1 (3.8%) | <25:1 (5.5%) 25-34:1 (5.5%) 35-44:4 (22.2%) 45-54:11 (61.1%) 55-64:1 (5.5%) |                                                    |
| Early Dialogues with HTA and regulators | Women: 14 (70%) Men: 6 (30%) | Women: 13 (72.3%) Men: 5 (27.7%) | Women: 9 (75%) Men: 3 (25%) | Patients/Patient advocates/Pharmaceutical industry professional, HCP, Research and Academia, Regulator, Other |
|                              | 25-34:1 (5%) 35-44:4 (20%) 45-54:10 (50%) 55-64:5 (25%) | 25-34:1 (5.5%) 35-44:3 (16.6%) 45-54:9 (50%) 55-64:5 (27.7%) | 25-34:1 (8.3%) 35-44:3 (25%) 45-54:4 (33.3%) 55-64:4 (33.3%) |                                                    |

Note: Rounds one and two were conducted online. Round three was face-to-face. Where possible expertise, geographical spread and sex were balance throughout. Research Priority Setting (RPS): Denmark, Spain, Germany, Ireland, Italy, Netherlands, USA, France, Czech Republic and United Kingdom; Clinical Trial Design (CTD): United Kingdom, Germany, Belgium, Spain, Austria, Denmark, Canada, Netherlands, USA and France; Early dialogues with Regulators and Health technology Assessment bodies (ED): United Kingdom, Spain, Italy, Canada, France, Greece, Belgium and Sweden. Patients (including carers), and Patient advocates and patient organizations, Health-care professionals (HCP – clinical academics), Health Technology Assessment bodies (HTA), pharmaceutical companies (Pharma), Industry and Biotechnology companies (Biotech), other (include, but not limited to individuals that identify as their primary affiliation of; charity, consultant, independent expert, think tank, industry association, social association, funder, NGO’s, or identified as having multiple relevant affiliations).
2.3 | Stage 3: Three-step RAND modified Delphi methodology

The modified Delphi methodology is a recognized method for prioritization of diverse variables through consensus.\textsuperscript{15,26} Delphi questionnaires were developed based on the outputs from stages one and two, combined with a review of existing frameworks for PE.\textsuperscript{10} Experts for each of the Delphi panels were convened using a snowball method. Experts had to hold recognized expertise and experience within their topic panel in relation on PE to guarantee that the group reflected the view of a majority (initial expert group size; RPS = 24, ED = 26, CTD = 31) (Table 1).

Each panel was balanced as far as possible for geographical coverage and sex (see Table 1 and 2\textsuperscript{7} for additional results). The three Delphi panels were run in parallel and consisted of three rounds of progressive prioritization of criteria and their corresponding categories. Rounds one and two were conducted via an online survey, and round three was a face-to-face meeting. During rounds one and two, experts were asked to judge individually how relevant each question was using a Likert scale [from 1 (not relevant at all) to 9 (highly relevant)]. Mean, median, coefficient variation (CV), interquartile range (IQR) and quartile 1 (Q1) were calculated along the vote distribution. Agreement was reached for those questions when Q1 ≥ 7, IQR ≤ 1, CV < 20\%; and when the median and the votes fitted within the same bracket (agreement converged around ‘relevant’) by the experts. Questions were dropped when Q1 ≤ 6, IQR ≥ 2, CV > 20\% and there was agreement when the median and votes fitted within the ‘irrelevant’ or ‘not clearly relevant’ bracket. The rest of the questions that did not reach any agreement were kept for reassessment for the second round where participants were given round one results and asked to individually re-score and order the categories – this included questions where previously no agreement was reached. Round three aimed to i) reach consensus among the items on which there was disagreement; ii) merge and rephrase criteria and categories; iii) weight categories within criteria; and iv) weight individual criteria.

3 | RESULTS

Here we present the findings of each of the three stages and the overall conclusions. Additional results are available at: https://imiparadigm.eu/our-work/\textsuperscript{28}
3.1 | Survey general characteristics

A total of 372 respondents completed the survey in English (Table 2). The largest respondent (stakeholder) group was the patient community (patients (including carers), patient advocates and/or patient organizations) (35.8%), followed by industry (34.9%). Respondents completed the survey from 48 countries – a majority from the UK and United States (28.2% and 16.9%, respectively) (Figure 2). The group ‘Other’ comprised 36 countries, both within and outside the European Union (18%, n ≤ 5 respondents from each).

3.2 | Survey responses

3.2.1 | What is the status quo of PE today?

Current perception of PE is low but ideal expectations are high.

Current expectations of PE were similarly low across all stages of the medicines’ lifecycle with the lowest expectations around HTA assessment, reimbursement and ED (Figure 3). Conversely ideal expectations of PE were similarly high across all six stages. The largest difference between current and ideal expectations of PE was at the ED stage.

3.2.2 | What are the challenges experienced with other stakeholders in their previous PE collaborations?

Stakeholders acknowledge the challenge that patient input was not part of decision making.

Of the 13 specified challenges in the survey question, the top overall challenge was, ‘Patient input was not part of decision making’. This was also the top challenge for research and academia, HTA bodies, research funders and payer groups. It was joint top with the industry group along with, ‘Delays in activities due to bureaucratic processes’. However, for the patient community this was less of an issue as the two top challenges were, ‘Communications were not clear and open’ and a ‘Lack of shared vision/goals’ (Figure 4).

3.3 | What are the desired outcomes of PE?

Greater patient-centric input, patient-relevant outcomes and communication are desired the most.

Respondents were asked to indicate up to three most desired outcomes of PE from a separate list of predefined outcomes for each of the three stages. The top three are as follows (see also Supplementary Table 1 A-C):

Research priority setting: i) When patients’ needs are leading in the research agenda, ii) when it results in new insights and new perspectives for policymakers and regulators and research funders and iii) when researchers get better insight in the patients’ journey.

Clinical trial design: i) When it results in more patient-relevant outcomes for clinical trials, ii) when patients can share their experiences and increase knowledge of the clinicians and iii) when it leads to higher patient satisfaction during the trial.

Medicines licensing and Health Technology Assessment: i) When the voice of the patient is reflected in the decision, ii) when patients’ needs are better met and iii) when it results in improving transparency and openness in decisions.

United Kingdom
Other (n=5)
United States
Belgium
Switzerland
Germany
Netherlands
Italy
Canada
France
Ireland
Spain
Denmark

FIGURE 2 | Total Survey respondents per country (Counts (N)). The group ‘Other’ comprised of countries with n ≤ 5 respondents each from: Afghanistan, Albania, Australia, Austria, China, Cyprus, Czech Republic, Finland, Greece, Hong Kong, India, Indonesia, Israel, Japan, Kazakhstan, Lithuania, Luxembourg, Macedonia, Malaysia, Malta, Moldova, Nepal, Norway, Philippines, Poland, Portugal, Romania, Serbia, Singapore, Slovenia, South Africa, South Korea, Sweden, Turkey, Uganda, Ukraine
A majority of industry respondents stated that they have a dedicated PE function in their organization (n = 99/130). The largest proportion of industry activities are ‘regularly engaged’ in clinical trial design (n = 46) and only ‘sometimes engaged’ at the research priority setting (n = 43) and at the licensing, HTA and pricing and reimbursement decisions stages (n = 51), respectively (Figure 5). Just over half of industry respondents stated they have a standard operating procedure (SOP) or other guidance on interactions with patients/patient organizations in place, and it is used in practice (n = 67/130). Conversely, three quarters do not have ‘Metrics or methods to determine impact of patient involvement’ (n = 103/130).

With respect to regulators, policymakers, HTA bodies and payers, and research funder groups, half of respondents (n = 12/23) reported that they have a dedicated PE function within their
FIGURE 5  Proportion of industry dedicated to each of three stages of medicines development for patient engagement activities (Total counts). Industry respondents could select one of five options for each of the three key stages

FIGURE 6  How prepared health-care professionals (A) and patient organizations (B) are to undertake PE activities (total counts). HCP and PO respondents could select more than one process responses required at each of the four levels of preparedness in a matrix question
organization. Nearly half of HCP respondents (n = 11/25) indicated that they do not have a SOP in place and it needs to be established and three quarters indicated that they do not have ‘Metrics or methods to determine the impact of PE’ (n = 20/25).

Additionally, patients and patient organizations, and HCP were asked if, ‘their organization was prepared to actively participate in PE’. Both stakeholder groups reported similarly that they are mostly ‘prepared but still require support’. Patients and patient organizations indicated that their greatest needs were ‘knowledge’ (n = 56) and ‘internal processes’ (n = 48). (Figure 6 A and B), yet HCP needed support similarly under every element listed ‘internal processes’, ‘knowledge’, ‘human resources’, ‘financial resources’, ‘managing competing interests’ and ‘setting priorities in your patient engagement strategy’.

3.3.2 | What is necessary to conduct more effective PE?

All stakeholders need metrics to measure impact and better methods on how to do more effective PE.

Out of the nine options given, ‘A way to measure the impact’ was selected most frequently overall (n = 272) followed by, ‘Methods, materials and information on how to do more effective patient engagement’ (n = 177) (Figure 7). When broken down by stakeholder group, stakeholder priorities differed slightly. The research and academia group most frequently reported that they required, ‘Training on how to implement PE processes in your organisation’ (n = 22), HTA respondents required ‘Methods, materials and information on how to do more effective patient engagement’ (n = 8), and the patient community, equally reported that they needed both ‘A way to measure the impact’ (n = 29), and ‘Methods to identify and evaluate where your contribution would be most valuable’ (n = 29).

3.3.3 | Is additional support for the patient community needed?

Patients, patient advocates and patient organizations need additional dedicated support.

Overall the patient community indicated that their greatest preference was for, ‘One-to-one support given directly to individual patients’ (n = 77/133). Specifically, a majority of patient respondents (ie not including patient organizations/advocates) indicated they would prefer support from a, ‘Person or group with in-depth knowledge about the area of the planned engagement’ (n = 28/45), while a majority of patient advocates or patient organization respondents would prefer, ‘Other stakeholders who are responsible for the activity I (we) want to engage in’ to provide support (n = 61/88) (for full details see 29).

Consultations: Increasing and supporting involvement of potentially vulnerable populations in PE.

Incorporating the lived experience and accommodating reasonable adjustments help to recognize and acknowledge the value patients bring.

Several common barriers to increasing and sustaining patient involvement emerged from the consultations with young people, and people with dementia and their carers, along with recommendations to overcome these (Table 3).

Understanding and incorporating the ‘lived experience’ of the patient (and not just the parent or carer) was considered to be paramount in adding genuine value to a given PE activity and in reflecting the expected outcomes. This can also serve to readdress many misconceptions of people with dementia and young people – namely

![FIGURE 7](https://example.com/figure7.png)

**FIGURE 7** What is required to do more effective patient engagement (total respondents). All stakeholder responded. Respondents could select more than one option. In the ‘Other’ category, additional resources highlighted included ‘a clear framework and guidelines on how to engage with patients’ and ‘funding/financial support from other stakeholders, particularly in providing funding/reimbursement/tokens of gratitude for patients’
that they are not able to or willing to be involved, an incorrect understanding of the condition(s) that they are living with, the added value that they can contribute, and the specific considerations (physical, mental, socioeconomic) of these populations.

The diversity of the patients involved in any PE activity was considered important to allow the broad range of experiences patients could contribute and provide equal opportunities for those who can be involved to do so. For example, different age groups,
gender, cultural background and for people with dementia, the type and stage of dementia, all present a diverse set of experiences to consider. The person(s) to be involved should have enough information and understanding of the PE activity itself, so that they can make an informed decision about participation and that they can be effectively engaged throughout. For example, information should be provided both before and during the PE activity in clear, accessible formats that are language and age appropriate, using enhanced text, contrast, short sentences and bullet points whenever possible.

Raising awareness and enhancing PE opportunities for people could be facilitated through modifications to structured protocols for PE. These include reasonable adjustments for travel and accommodation; reimbursement of incurred cost that includes carers or additional help needed, utilizing time slots that are outside of school hours for young people, and providing support and accessible information to patients and carers and/or training, if appropriate, ahead of the PE activity. General information provided in advance can include topic areas to be discussed and any additional questions about the topic in question. For the other stakeholder(s) that are managing the topic areas to be discussed and any additional questions about the PE activity, there could be a single trusted point of contact for the patients and their carers to have access to throughout the PE process.

**Workshop: Taking better account of HTA bodies considerations of PE in ED.**

**TABLE 4 Major challenges identified with patient engagement (PE) in early dialogues (ED) † from a focus group with Health Technology Assessment (HTA) bodies**

| Common challenges of patient engagement (PE) in ED | Types of tools, resources and guidance needed to improve PE in ED |
|------------------------------------------------------|--------------------------------------------------------------|
| Patients are unable to make objective inputs          | Patient recruitment processes                                 |
| Difficulties finding patients (appropriate profile and capacity) | including developing criteria and guidance to help HTA bodies find, select and enrol patients into the early dialogue processes. |
| Details are too complex for patients to engage with    | Patient interview guidance                                   |
|                                                      | including interview guides, standard questionnaires and guidance on adapting them to particular early dialogue topics. |
| Conflicts of interest between patient organizations and industry | Minimum standards framework                                   |
|                                                      | including a framework of methods with guidance on their use, guidance for meeting chairs and patients and adaptation to meeting formats to accommodate specific patient needs. |
| Lack of internal resources (time, financial)          | Rationale for PE in Early Dialogues                           |
|                                                      | including metrics that show the impact of PE, case studies demonstrating how this can be achieved, definitions of early dialogues and better articulated rationale for PE. |

Note: Participants were: Instituto Aragonés De Ciencias De La Salud (IACS) Spain, The National Institute for Health and Care Excellence (NICE) UK, Haute Autorité de santé (HAS)/ European Network for Health Technology Assessment (EUnetHTA) France/EU, Norwegian Medicines agency (NOMA) Norway, Reggio Emilia Local Health Authority (RER) Italy, Tandvårds- & läkemedelsförämningsverket or The Dental and Pharmaceutical Benefits Agency(TLV) Sweden, Canadian Agency for Drugs and Technologies in Health (CADTH) Canada. NB † Early dialogue is not considered a decision-making time for any party. In practice it more closely resembles consultation with the chance for feedback and input (two-way communication). Adapted from Bertelsen N, et al, 2020, under submission to Health Expectations
Delphi Method: Translating identified needs, expectations and preferences into agreed criteria for enhanced PE.

The first two Delphi rounds resulted in many criteria being modified or dropped (see 28). Notably, at the category level, Sustainability was dropped after round two for ED. While experts recognized the importance of Sustainability of PE practices in ED, it was of a lesser current focus compared to other stages of medicines development. For the other two key stages, Sustainability was ranked equally low. Conversely, the category, Aims and objectives (and related category, Key elements of practice design, which included aims and objectives) were ranked similarly high across all three key stages. Criteria within this category centred on that the aims and objectives of PE practices should meet the expectations of patients and/or focus on patients’ needs and interests. They should also be agreed upon up front by all and be understandable to all involved participants (see Supplementary Tables 2-4).

At the criteria level overall, there were differences in the wording and definitions, across the three key stages (Table 5), the main difference, however, was in their respective weightings. The following general criteria were thus fairly consistent in their definition, across categories and the three key stages:

3.4 | Involvement and participation

Patients’ participation should be properly planned, taking into account timing requirements, accessibility and vulnerability. More specifically, it should consider specific patient’s circumstances and characteristics linked to but not limited to possible physical or mental impairments, cultural background, age and other relevant features (eg recordings, virtual communication and use of language, format of meetings, the venue and information provided). Additionally, an up-to-date single point of contact or a named person with whom patients can communicate when needed for information and/or support, is made available throughout their involvement in the activity (eg during ED).

3.5 | Legal and ethical considerations that govern PE – including a code of conduct

It is necessary to have any relevant policy directives, legal, ethics, governance requirements and/or regulatory framework about how to engage patients included as part of PE practices. More specifically, ensuring that codes of conduct are adhered to and conflicts of interest are addressed and managed through accountability and transparency. Notably, participants raised as yet unresolved considerations of how to effectively balance conflicts of interests with suitable patient participation.

3.6 | Building capacity to support the PE process

The competencies that are required to perform the PE activity itself need to be identified and actioned appropriately (eg in setting research priorities by all participants). Any training material should be adapted, comprehensible and accessible to all involved participants and take into consideration any impairments, literacy levels, cultural

| Setting research priorities | Designing clinical trials | Early dialogues with regulators and HTA |
|-----------------------------|---------------------------|----------------------------------------|
| Criteria                    | Weight                    | Criteria                                | Weight | Criteria                                | Weight |
| Key Elements of Practice Design | 19.5                      | Aim and objectives                       | 14     | Aim and objectives                       | 17.9   |
| Resources                   | 16                        | Patient engagement impact                | 14     | Target participants involved in patient engagement | 15.3   |
| Evaluation of the PE Practice in Setting Research Priority | 12                        | Target patients involved                 | 12     | Involvement and participation            | 14.7   |
| Capacity Building           | 12                        | Legal and ethical consideration          | 11     | Code of conduct                         | 11.3   |
| Patient Engagement Impact   | 11.5                      | Involvement and participation            | 11     | Capacity building                       | 11.1   |
| Involvement and Participation| 11                        | Resources                                | 10     | Resources                               | 10.9   |
| Code of Conduct             | 10                        | Capacity building                        | 10     | Patient Engagement Impact               | 10     |
| Sustainability              | 8                         | Evaluation of the PE practice in the Design of Clinical Trials | 10 | Evaluation                              | 8.8    |

Table 5: Final list of major categories and respective weighting for effective patient engagement (PE), based on the consensus of three panel three round Delphi method.

Note: The final Delphi round aimed to i) reach consensus among the disagreement items not obtained after the first and second round; ii) Merging and rephrasing criteria and categories; iii) weighting categories; iv) weighting individual criteria. Starting from a list of approx. 50 questions for each decision point, after round 3 this was reduced to an agreed 20-25 criteria separately for each key stage of medicines development, positioned under 8 or 9 major categories. All weightings across categories and criteria within each category, equate to 100. The full breakdown of round 1 and 2 results can be seen at 28.
backgrounds and the circumstances of potentially vulnerable patients involved in setting research priorities.

3.7 | Evaluation of the PE process

Generally, methods, tools and monitoring systems should be in place to evaluate the PE practice, including a framework. An evaluation of the outcomes should be linked to the aims and objectives of the PE practice in each setting. Additionally, the outcomes should be shared with all the participants involved and procedures should be in place so that the conclusions of the evaluation are used to support a continuous improvement process.

3.8 | Synthesis of findings

3.8.1 | Stakeholders’ needs, expectations and preferences

Stakeholders continue to acknowledge that PE is crucial throughout the medicines development process and it needs to improve.2,3,8 There is a strong desire that PE has a greater focus on incorporating patient insights and expertise, that it results in better patient-relevant outcomes, and that the patient voice is reflected in the decision-making process. This last point was the top rated difficulty identified, that is, that patients are not involved in a decision-making process; they are more often engaged at a lower level of involvement.30 This is nuanced in the case of ED with HTA, in that unlike other HTA processes where patients are involved, ED is not in itself a decision-making process, so the expectations for HTA bodies and patients here need to be considered differently while sharing best practices globally. Frameworks to measure impact, a return on engagement and methods to undertake more effective PE, that are supported by exemplars of good practice, were needed most. Yet the patient community’s needs focused more on the need for better communication and an alignment of shared vision. This may reflect the current focus and greater experience at CTD compared to other key stages of RPS and ED. It could be argued that the focus at CTD is partly driven by the desire to demonstrate quantitative downstream effectors [of PE] such as time and budget savings and increased recruitment rates,19 whereas at RPS and ED stages more useful measures are qualitative and more reflective of patient-centred outcomes (such as empowerment and equality) and patient-relevant research or endpoints.31,32 Improvements at the RPS and ED stages could be best focused on more upstream effectors on methods and structures on how to do PE more effectively and that better align with patients’ expectations. At a strategic level, alignment between stakeholders on the positive rationale for involving patients in RPS and ED and how to effectively incorporate or utilize patient insights in their work can continue through EU and global platforms.33-37

Understanding and incorporating the lived experience of the patient was considered a paramount expectation for effective engagement. For the populations included here – people with dementia and young people, systematic efforts are limited by many of the reasons reported here.17,38 Combining the results here with recent advances involving minors in medicine development within The publication ‘Principles on the involvement of young patients/consumers within the European Medicines Agency (EMA) activities’ 17 has established the first framework at the European level to promote the involvement of minors in medicines development from the regulatory perspective and can be built upon by others. and existing training platforms like the European Patients Academy (EUPATI) or the European Organisation for Rare Diseases (EURORDIS) Open Academy39 provide training of patients that can be supplemented by additional specific methodologies for interacting with potentially vulnerable populations, for example through KIDS Barcelona.40

3.9 | Stakeholder support, resources and training

Most stakeholders felt confident and ready to engage in a PE activity, but need continued and improved support mechanisms to do so, especially on the ‘how to do better PE’. The patient community needs extra support through expertise of the particular stakeholder and decision-making process in question, and one-to-one mentorship of individual patients. This is currently often done through stakeholder specific networks and training programmes.39,41

However, continued engagement with other stakeholder groups (such as regulators,31,42-44 HTA,45,46 industry47,48 working party and advisory groups12 ) can provide the much needed continuous bilateral knowledge exchange underpinned by a growing literature on successful multi-stakeholder dialogues and engagement practices.49,50 The variety of approaches by HTA bodies reflects a very different expectation, capacity and support needs by this stakeholder group to engage patients in ED. Patients are being involved in dialogues with some HTA bodies more consistently where resources allow; however, perceptual and practical barriers still exist across many HTA bodies. Leadership is gathering momentum through, for example, EUneHHTA and bodies like HTAi PCIG who share good practice and run workshops about PE in HTA at annual meetings. The rate of evolution here will likely be at a different rate from industry and regulators.

3.10 | Enabling criteria for effective PE

The criteria identified here represent a common language and alignment across stakeholders on engagement approaches across the life cycle of medicines development. Despite some obvious and understandable stakeholder divergence on the categories and criteria for optimal PE, there was convergence of some of the weighted categories and criteria within them across the three
stages of medicines development. Namely, the strong agreement upfront in the design part of the PE practice (i.e., aim and objectives) suggests that good PE can emerge as a consequence of good practice design. The full considerations of all patients involved be accounted for in the planning, implementation, reflection, evaluation, and communication phases of the PE process. This includes improving inclusivity of, and accounting for, specific needs of potentially vulnerable populations. The PE approach itself is underpinned by adherence to all relevant ethical and legal considerations that are relevant for, available to, and understandable by patients in a clear and accessible way. Measuring the value of the engagement itself – the return on engagement – should be substantive, logical, and prospectively planned. Importantly, all Delphi criteria were agreed as important; thus, all should be taken into account during the planning, implementation, and reflection of PE activities as part of the required cultural and practical evolution of addressing many of the barriers to PE. \(^{51}\)

3.11 | Co-creation and coordinated actions for the evolution of PE

Creating methods, frameworks, and guidance that address the varying stakeholder needs are complex. ‘One size does not (and should not) fit all’, and no single leader is needed. Instead, collective leadership and the co-creation of solutions are needed via a ‘building block’ approach. These foundations are built on a detailed understanding of needs, expectations, and preferences for effective PE in a multi-stakeholder environment – as described here. This is complemented by demonstrating the value of PE more definitively through a monitoring and evaluation framework that is relevant, context specific, and impact can be demonstrated through real case studies combined with materials adaptable to stakeholder needs.\(^{52}\) Combining these with other practical elements such as tools, and clear signposting to stakeholder specific material within regional and national networks\(^{33,34,53-56}\) will enable an approach to PE that is most appropriate to the stakeholder(s) involved and specific question(s) being asked.

From the reported perspective of HTA bodies, the proposed ‘building block’ approach allows work to progress in parallel and at a different rate to other stakeholders and geographies, but remain linked and sympathetic to an evolving ecosystem approach to PE.

3.12 | Limitations

The online survey was completed only by those who are familiar with and access to the technology, and a good understanding of English. The survey included questions that covered PE generally across medicines development and at three specific stages; these included broad and specific HTA process involving patients. Although piloted, it was impossible to identify how respondents interpreted the questions in the wider context, and where English was not their first language. Despite snowball techniques being used to maximize stakeholder reach, responses were dominated by patient and industry communities, and the central EU and North America regions; thus, the interpretation of conclusions for other stakeholder groups and countries outside these regions should be taken cautiously. Extending such a survey to non-English languages would enrich applicability of future research findings. A temporary technical issue with the survey administration meant that we purposefully excluded any partially completed responses from the analysis. This resulted in reduced total response numbers, although we exceeded the minimum required response number of 370.

The consultations were relatively diverse with respect to experience of medicines development, geography, and for those with dementia, a range of dementia types. However, hard to reach groups and ethnic minorities may not have been sufficiently covered. Health-care professionals represent a diverse group (general practitioners, nurses, clinical investigators/academics and pharmacologists). However, taking into account the low level of maturity towards PE, their diversity, and the 3 decision points chosen here, we prioritized clinical academics. There are a vast number of HTA bodies across the EU and North America, some currently active in ED, many not. A generalization of reported themes across all HTA bodies and geographies is not appropriate at this time.

Finally, there were dropouts of Delphi panellists during the process for a variety of reasons. In the CDT Delphi group, many respondents were from North America; hence, some bias in interpretation of responses and weightings was inevitable. Despite this, the overall number and expertise balance within and between each group was monitored, and stakeholders’ representativeness were not at risk.

4 | CONCLUSION

This multi-stage study adds significant value by building on some of the previously identified gaps between stakeholder specific understanding and importance of PE, and who should be responsible for leading efforts to improve it.\(^{8,15,31}\) These findings provide detailed and tangible building blocks to all involved stakeholders as to where stakeholder needs and expectations are, and where greater alignment could occur. The work of the PARADIGM consortium and its partners continue to address many of these signals holistically through multi-stakeholder mechanisms\(^{35,37,57}\) in the continued evolution of meaningful, ethical, and sustainable PE.

ACKNOWLEDGEMENTS

The authors gratefully acknowledge all those PARADIGM consortium members who helped design, test and validate the survey and Delphi materials. We thank all those survey participants and Delphi panellists who dedicated their time to help make these a success and to those participants who participated in the face-to-face consultations facilitated by Alzheimer Europe (European Working Group of People with Dementia, EWGPWD), the KIDS Barcelona Young Person’s Advisory Group (YPAG) for
their expertise and patience. We also thank all those HTA bodies and working groups who helped design the scoping questions and session; HTA International Patient and Citizens Involvement in HTA Interest Group, HAS (France), NICE (England), CADTH (Canada), SMC (Scotland), as well as a representative from the European Network for HTA Agencies (EUnetHTA) Early Dialogues Working Party, and those HTA bodies and PARADIGM consortium members who provided rich input during the workshop for HTA international (HTAi); IACS Aragon (Spain), NICE (UK), CADAH (Canada), TLV (Sweden), HAS (France), NOMA (Norway), RER (Italy) and EUnetHTA (Europe). NF is supported by the NIHR Oxford Biomedical Research Centre.

CONFLICT OF INTEREST
The following authors have no conflicts of interest to disclose:
SDF, SSi, CP, FS, MJVE, LPR, ADP, DG, EF, BF, NB, AM, MB and NF.

NB works with a variety of stakeholder groups on patient involvement in health-care decisions. This includes work as a consultant to patient groups and to the industry.

This work was funded under EU IMI grant agreement number 777 450 – PARADIGM (Patients Active in Research and Dialogues for an Improved Generation of Medicines).

AUTHOR CONTRIBUTIONS’
All authors contributed to the design of this study and the writing of this paper.

Authors SDF, SSi, CP, MJVE, LPR, ADP, DG, EF, BF and NB also contributed to data analysis.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Stuart D Faulkner https://orcid.org/0000-0002-6345-5323
Suzanne Sayuri Ii https://orcid.org/0000-0002-5128-0300
Neil Bertelsen https://orcid.org/0000-0003-3235-5810
Nick Fahy https://orcid.org/0000-0003-4957-0189

REFERENCES
1. Abma TA, Pittens CA, Visse M, Elberse JE, Broerse JE. Patient involvement in research programming and implementation: A responsive evaluation of the Dialogue Model for research agenda setting. Health Expect. 2015;18(6):2449-2464.
2. Boutin M, Dewulf L, Hoos A, et al. Culture and process change as a priority for patient engagement in medicines development. Ther Innov Regul Sci. 2017;51(1):29-38.
3. Hoos A, Anderson J, Boutin M, et al. Partnering with patients in the development and lifecycle of medicines: a call for action. Ther Innov Regul Sci. 2015;49(6):929-939.
4. Perfetto EM, Burke L, Oehrlein EM, Epstein RS. Patient-focused drug development: a new direction for collaboration. Med Care. 2015;53(1):9-17.
5. Pushparajah DS. Making patient engagement a reality. Patient. 2018;11(1):1-8.
6. Supple D, Roberts A, Hudson V, et al. From tokenism to meaningful engagement: best practices in patient involvement in an EU project. Res Involv Engagem. 2015;1:5.
7. Paradigm IMI. 2018; https://imi-paradigm.eu/. Accessed Jan 18th 2019.
8. Boudes M, Robinson P, Bertelsen N, et al. What do stakeholders expect from patient engagement: Are these expectations being met? Health Expect. 2018;21(6):1035-1045.
9. Deane K, Delbecque L, Gorbenko O, et al. Co-creation of patient engagement quality guidance for medicines development: an international multistakeholder initiative. BMJ Innovations. 2019:bmjinnov-2018-000317.
10. Synapse. Patient engagement quality guidance. 2018; https://patientfocusedmedicine.org/the-patient-engagement-quality-guidance/. Accessed Jan 31st, 2019.
11. Principles on the involvement of young patients/consumers within EMA activities. 2017. https://www.ema.europa.eu/documents/regulatory-procedural-guideline/principles-involvement-young-patients/consumers-within-ema-activities_en.pdf. Accessed Aug 1st 2019.
12. INVOLVE. Involving children and young people in research: top tips and essential key issues for researchers. 2016. http://www.invo.org.uk/wp-content/uploads/2016/01/involvingcyp-tips-keyissues-January2016.pdf. Accessed Aug 1st 2019.
13. Eichler HG, Bedlington N, Boudes M, et al. Medicines Adaptive Pathways to Patients: Why, When, and How to Engage? Clin Pharmacol Ther. 2019;105(5):1148-1155.
14. Mechanism of Coordinated Access to orphan medicinal products (MoCA). 2017; https://www.eurordis.org/content/moca. Accessed Aug 1st, 2019.
15. Parsons S, Starling B, Mullan-Jensen C, Tham SG, Warner K, Wever K. What do pharmaceutical industry professionals in Europe believe about involving patients and the public in research and development of medicines? A qualitative interview study. BMJ Open. 2016;6(1):e008928.
16. Parsons S, Starling B, Mullan-Jensen C, et al. What the public knows and wants to know about medicines research and development: a survey of the general public in six European countries. BMJ Open. 2015;5(4):e006420.
17. Gove D, D-PA, Georges J, Moniz-Cook E, Mountain G, Chattat R, Øksnebjerg L; European Working Group of People with Dementia. Alzheimer Europe’s position on involving people with dementia in research through PPI. Aging Ment Health. 2018;22(6):723-729.
18. Roberts C, Rochford-Brennan H, Goodrick J, Gove D, Diaz-Ponce A, Georges J. Our reflections of patient and public involvement in research as members of the European Working Group of People with Dementia. Dementia (London). 2020;19(1):10-17.
19. Levitan B, Getz K, Eisenstein EL, et al. Assessing the financial value of patient engagement: a quantitative approach from CTTI’s patient groups and clinical trials project. Ther Innov Regul Sci. 2018;52(2):220-229.
20. Patrick-Lake B. Patient engagement in clinical trials: The Clinical Trials Transformation Initiative’s leadership from theory to practical implementation. Clin Trials. 2018;15(1 suppl):19-22.
21. European Working Group of People with Dementia. 2012-present; https://www.alzheimer-europe.org/Alzheimer-Europe/Who-we-are/European-Working-Group-of-People-with-Dementia. Accessed Aug 1st, 2019.
22. Consultation on Patient Engagement in development of medicines in dementia. IMI PARADIGM website2018.
23. Pakarinen C, et al.D1.1 Survey analysis report on stakeholder-specific preferences, needs and expectations. IMI PARADIGM
24. Nafría B. Report for consultation with young persons: KidsBarcelona. IMI PARADIGM website 2018. https://imi-paradigm.eu/Paradigm-documents/Report-for-consultation-with-young-persons-FSJD-final.pdf

25. Hutchings A, Raine R, Sanderson C, Black N. A comparison of formal consensus methods used for developing clinical guidelines. J Health Serv Res Policy. 2006;11(4):218-224.

26. Eubank BH, Mohtadi NG, Lafave MR, et al. Using the modified Delphi method to establish clinical consensus for the diagnosis and treatment of patients with rotator cuff pathology. BMC Med Res Methodol. 2016;16:56.

27. Maria Jose Vicente Edo LP, et al. Criteria to assess how patient engagement expectations are met. IMI PARADIGM 2019. https://imi-paradigm.eu/Paradigm-documents/D1.2Criteria-for-assessing-how-PE-expectations-are-met-practices.pdf

28. PARADIGM. Patients active in research and dialogues for an improved generation of medicines. 2018; https://imi-paradigm.eu/our-work/. Accessed July, 2020.

29. PARADIGM. Survey analysis report on stakeholder-specific preferences, needs and expectations. 2019; https://imi-paradigm.eu/wp-content/uploads/2019/03/D1.1-Survey-analysis-report.pdf. Accessed July, 2019.

30. Arnstein SR. Ladder of Citizen Participation. J Am I Planners. 1969;35(4):216-224.

31. Bellows MKB, Katharina; Jackson K, Surgeoner B and Gallivan J. Meaningful and effective patient engagement: What matters most to stakeholders. Patient Experience Journal. 2015;2 (Iss. 1:Article 5.).

32. Vat LE, Finlay T, Jan Schuitmaker-Warnaar T, et al. Evaluating the “return on patient engagement initiatives” in medicines research and development: A literature review. Health Expect. 2020;23(1):5-18.

33. Clinical Trials Transformative Initiative. 2007; https://www.ctti-clinicaltrials.org/. Accessed Aug 1st, 2019.

34. PCORI. 2011; https://www.PCORI.org/about-us/our-programs. Accessed Aug 1st, 2019.

35. European Patients’ Academy. 2012; https://www.eupati.eu/. Accessed Aug 1st, 2019.

36. The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER). 2016; http://www.imi-prefer.eu/. Accessed Aug 1st, 2019.

37. Synergist. PFMD. 2015; https://patientfocusedmedicine.org/about-pfmd/. Accessed Aug 1st, 2019.

38. Bethell J, Commino E, Rostad HM, et al. Patient engagement in research related to dementia: A scoping review. Dementia (London). 2018;17(8):944-975.

39. Diseases EOfR. European Organisation for Rare Diseases (EURODIS) Open Academy 2020; https://openacademy.eurodis.org/. Accessed July, 2020.

40. McRorie JW Jr. Evidence-Based Approach to Fiber Supplements and Clinically Meaningful Health Benefits, Part 1: What to Look for and How to Recommend an Effective Fiber Therapy. Nutr Today. 2015;50(2):82-89.

41. EUPATI. 2012-2017; https://www.EUPATI.eu/. Accessed June 2018.

42. Revised framework for interaction between the European Medicines Agency and patients and consumers and their organisations. 2014. Accessed Aug 1st 2019 http://www.ema.europa.eu/docs/en_GB/document_library/Other/2009/12/WC500018013.pdf

43. Training and resources for patients and consumers 2014–2017; https://www.ema.europa.eu/en/partners-networks/patients-consumers/training-resources-patients-consumers Accessed Jan 31st, 2019.

44. European Medicines Agency policy on the handling of competing interests of scientific committees’ members and experts. 2016. https://www.ema.europa.eu/documents/other/policy-44-european-medicines-agency-policy-handling-competing-interests-scientific-committees_en.pdf. Accessed Sept 2018.

45. Values and standards for patient involvement in. hta. 2014; https://htai.org/interest-groups/pcg/values-and-standards/. Accessed Sept 2018.

46. Willemsen A, Guilhaume CG. Patient consumer healthcare provider involvement eunetha ja. European Network for HTA April 18th 2018. https://www.ema.europa.eu/en/documents/presentation/presentation-patient-consumer-health-care-provider-involvement-ja-eunetha-ja-emas-pcwp-hcwpjoin_final_en.pdf

47. Kay Warner WS, Haerry D, Klingmann I, Hunter A, May M. EUPATI Guidance for Patient Involvement in Medicines Research and Development (RandD). Guidance for Pharmaceutical Industry-Led Medicines R&D. 2018. https://www.frontiersin.org/articles/10.3389/fmed.2018.00270/full. Accessed 2019.

48. EFPIA Think Tank. Working together with patient groups. European Federation of Pharmaceutical Industry Associations website 2017. https://www.efpia.eu/media/288492/working-together-with-patient-groups-23102017.pdf

49. Brown P, Bahri P. ‘Engagement’ of patients and healthcare professionals in regulatory pharmacovigilance: establishing a conceptual and methodological framework. Eur J Clin Pharmacol. 2019;75(9):1181-1192.

50. Soekhai V, Whichelco C, Levitan B, et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. Drug Discov Today. 2019;24(7):1324-1331.

51. Smith MY, Hammad TA, Metcalf M, et al. Patient engagement at a tipping point: the need for cultural change across patient, sponsor, and regulator stakeholders: insights from the DIA Conference, “Patient Engagement in Benefit Risk Assessment Throughout the Life Cycle of Medical Products”. Ther Innov Regul Sci. 2016;50(5):546-553.

52. Greenhalgh T, Hinton L, Finlay T, et al. Frameworks for supporting patient and public involvement in research: Systematic review and co-design pilot. Health Expect. 2019.22(4):801.

53. European Medicine Agency, 2019; https://www.ema.europa.eu/en. Accessed Aug 1st, 2019.

54. HTAI. 2019; https://htai.org/. Accessed Aug 1st, 2019.

55. European Organisation for Rare Diseases, 2019; https://www.eu-rodis.org/. Accessed Aug 1st, 2019.

56. European Patients Forum, 2014–2020; http://www.eu-patient.eu/. Accessed Aug 1st, 2019.

57. Innovative Medicines Initiative. 2019; https://www.imi.europa.eu/. Accessed Aug 1st, 2019.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.